An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Panitumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 16 Sep 2005 New trial record.